Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response

Autor: Nieuwkerk, P, Gisolf, E, Sprangers, M, Danner, S, Prometheus study group,, Ende, Marchina, Nouwen, Jan, Deenenkamp, R, van der Meyden, D

Publikováno v: Antiviral Therapy, 6, 97-103. International Medical Press Ltd

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::beb75826379f3b3b86daf1076fbf3ff4
https://pure.eur.nl/en/publications/c95a346c-8b09-42f2-b16f-6407b1eaa537

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine

Autor: Gisolf, E. H., Dreezen, C., Danner, S. A., Weel, J. L.F., Weverling, G. J., Reiss, P., Duurvoort, M., Krijger, E., Brouwer, E., Visser, G. R., Klotz, A., Benschop, C., Wulfert, F., Wolf, F. De, Jurriaans, S., Portegies, P., Colebunders, R., Pelgrom, J., Wijnants, H., DE Roo, A., Keersmaekers, K., Vandenbruane, M., Branden, D. Van Den, James, T., Wanzeele, F. Van, Gucht, B. Van Der, Van Der Ende, M. E., Nouwen, J., Deenenkamp, R., Van Der Meyden, D., Koopmans, P. P., Brinkman, K., Ver Hofstede, H., Zomer, B., Blok, W. L., Ruissen, C., Sprenger, H., Law, G., Meulen, P. Vander, Veen, C. Ten, Juttmann, J. R., Heul, C. Vander, Santegoets, R., Ven, B. Vander, Kate, R. W.Ten, Schoemaker, M., Kauffmann, R. H., Henrichs, J. M., Maat, A., Prins, E., Napel, C. H.H.Ten, Pogany, K., Duyts, T., Simons, P., Lacor, P., Waele, A. De, Wijngaarden, E. Van, Lejeune, M., Nieuwkerk, P., Sprangers, M., Roos, M., Scholte, R., Dijkman, J., Japour, A. J., Borst, M. J., Leeuwen, E. Van

Publikováno v: Clinical Infectious Diseases, 31(5), 1234-1239. Oxford University Press
Clinical Infectious Diseases, 31(5), 1234-1239
Gisolf, E H, Dreezen, C, Danner, S A, Weel, J L F, Weverling, G J, Reiss, P, Weverling, G J, Duurvoort, M, Krijger, E, Brouwer, E, Visser, G R, Klotz, A, Benschop, C, Wulfert, F, Danner, S A, Wolf, F D, Jurriaans, S, Portegies, P, Colebunders, R, Pelgrom, J, Wijnants, H, DE Roo, A, Keersmaekers, K, Vandenbruane, M, Branden, D V D, James, T, Wanzeele, F V, Gucht, B V D, Van Der Ende, M E, Nouwen, J, Deenenkamp, R, Van Der Meyden, D, Koopmans, P P, Brinkman, K, Ver Hofstede, H, Zomer, B, Blok, W L, Ruissen, C, Sprenger, H, Law, G, Meulen, P V, Veen, C T, Juttmann, J R, Heul, C V, Santegoets, R, Ven, B V, Kate, R W T, Schoemaker, M, Kauffmann, R H, Henrichs, J M, Maat, A, Prins, E, Napel, C H H T, Pogany, K, Duyts, T, Simons, P, Lacor, P, Waele, A D, Wijngaarden, E V, Lejeune, M, Wijngaarden, E V, Lejeune, M, Nieuwkerk, P, Sprangers, M, Roos, M, Scholte, R, Dijkman, J, Japour, A J, Borst, M J & Leeuwen, E V 2000, ' Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine ', Clinical Infectious Diseases, vol. 31, no. 5, pp. 1234-1239 . https://doi.org/10.1086/317449
Clinical infectious diseases, 31, 1234-1239. Oxford University Press

Liver enzyme elevation (LEE) is commonly observed after combination antiretroviral therapy (ARVT) for HIV infection is begun. Potential risk factors for LEE after treatment with ritonavir and saquinavir with or without stavudine were investigated in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f615f6536c6a96e7085c25f5eb7ec42c
https://pure.eur.nl/en/publications/beadb3d0-5a2a-44c7-85c9-eaddd275ab6c